SEP 0 8 2006 W

Sheet 1

PTO/SB/08A (07-06)
Approved for use through 09/30/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE vaperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

TRADE Institute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

of 2

Complete if Known			
Application Number	10,622,302		
Filing Date	July 18, 2003		
First Named Inventor	Stec		
Art Unit	1617		
Examiner Name	D Clayton		
Attorney Docket Number	AI S-2		

			U. S. PATEN	DOCUMENTS	
Examiner Initials*	Cite No.1	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	ļ	Number-Kind Code ^{2 (# known)}			
		^{US-} 5,504,111	04-02-1996	Flavin et al	entire document
		^{US-} 2002/0013331 A1	01-31-2002	Williams et al	entire document
		US-			
		US-			
		US-			
··		US-			
		US-			
		US-			
		US-			
		US-	,		
		US-			
		US-			
		US-			
		US-	<u> </u>		
		US-			

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No.1	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages	
		Country Code ³ Number ⁴ Kind Code ⁶ (If known)	MM-DD-YYYY		Or Relevant Figures Appear	T⁵
	ļ	<u> </u>				<u> </u>
						-
						╄
				10.00		
		 				•

Examiner Date	
Signature Considered	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. Applicant is to place a check mark here if English language Translation is attached.

Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08B (07-06)
Approved for use through 09/30/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449/PTO	Complete If Known			
Substitute for form 1-4-37 10	Application Number	10/622,302		
INFORMATION DISCLOSURE	Filing Date	July 18, 2003		
STATEMENT BY APPLICANT	First Named Inventor	Stec		
(Use as many sheets as necessary)	Art Unit	1617		
(Use as many sneets as necessary)	Examiner Name	D. Clayton		
Sheet 2 of 2	Attorney Docket Number	ALS-2		

Examiner	Cite	NON PATENT LITERATURE DOCUMENTS Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of	
Initials*	No.1	the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
		TAO et al; Cardioprotective effects of thioredoxin in myocardial ischemia, Pharmacology, Vol 101, No. 31 p. 11471-11476, Pub: Nat'l Academy of Science, 08-03-2004	
		Eiznhamer et al; Effective attenuation of endotoxin induced acute lung injury by 2,3-diacetyloxybenzoic acid, Pulmonary Pharmacology & Therapeutics, Vol. 17 (2004),	
		(cont) p. 105-110, Pub: Elsevier Ltd., 11-26-2003	
		Ermakova, Influence of sodium salicylate, acetylsalicylate, 2,3-dihydroxybenzoic and 2,3-diacetoxybenzoic acids on the blood coagulation system; Farmakol Toksikol, 1975	
		(cont) 1975; 38:445-9 (Note: only abstract available; no additional information available)	

Examiner	Date	
Signature	Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.